Literature DB >> 20668448

Interpretation and inference in noninferiority randomized controlled trials in drug research.

G Wangge1, O H Klungel, K C B Roes, A de Boer, A W Hoes, M J Knol.   

Abstract

Noninferiority (NI) trials in drug research are used for the purpose of demonstrating that a new treatment is not worse than a proven active comparator, thereby indirectly showing that the treatment is effective. This article explains and addresses the complications in the interpretation of NI trials that arise from the indirect comparison. On the basis of our review of 232 trials, we conclude that the interpretation and inference of NI trials are complicated, partly because of the incompleteness of the information.

Mesh:

Substances:

Year:  2010        PMID: 20668448     DOI: 10.1038/clpt.2010.134

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants.

Authors:  Grace Wangge; Kit C B Roes; Anthonius de Boer; Arno W Hoes; Mirjam J Knol
Journal:  CMAJ       Date:  2012-08-20       Impact factor: 8.262

2.  Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach.

Authors:  Jeremy L Warner; Peter C Yang; Gil Alterovitz
Journal:  JCO Clin Cancer Inform       Date:  2017-11

3.  Topical or oral antibiotics for children with acute otitis media presenting with ear discharge: study protocol of a randomised controlled non-inferiority trial.

Authors:  Saskia Hullegie; Roderick P Venekamp; Thijs M A van Dongen; Sanne Mulder; Willem van Schaik; G Ardine de Wit; Alastair D Hay; Paul Little; Michael V Moore; Elisabeth A M Sanders; Marc J M Bonten; Debby Bogaert; Anne Gm Schilder; Roger A M J Damoiseaux
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

4.  Phase IV non-inferiority trials and additional claims of benefit.

Authors:  Rosemarie D L C Bernabe; Grace Wangge; Mirjam J Knol; Olaf H Klungel; Johannes J M van Delden; Anthonius de Boer; Arno W Hoes; Jan A M Raaijmakers; Ghislaine J M W van Thiel
Journal:  BMC Med Res Methodol       Date:  2013-05-30       Impact factor: 4.615

5.  Regulatory scientific advice on non-inferiority drug trials.

Authors:  Grace Wangge; Michelle Putzeist; Mirjam J Knol; Olaf H Klungel; Christine C Gispen-De Wied; Antonius de Boer; Arno W Hoes; Hubert G Leufkens; Aukje K Mantel-Teeuwisse
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

Review 6.  A clinician's guide to the assessment and interpretation of noninferiority trials for novel therapies.

Authors:  Simon J W Oczkowski
Journal:  Open Med       Date:  2014-05-06

Review 7.  Non-inferiority trials in cardiology: what clinicians need to know.

Authors:  James T Leung; Stephanie L Barnes; Sidney T Lo; Dominic Y Leung
Journal:  Heart       Date:  2019-10-31       Impact factor: 5.994

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.